We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more
Ask ADVFN Intelligence (AI)
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more...
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today...
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks— —Favorable safety and tolerability results with no new safety...
Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders On track to report topline data from the RewinD-LB...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -1.76211453744 | 2.27 | 2.38 | 2.21 | 96150 | 2.27014507 | CS |
| 4 | 0.059 | 2.7176416398 | 2.171 | 2.38 | 1.9853 | 119112 | 2.19112828 | CS |
| 12 | -9.16 | -80.4214223003 | 11.39 | 14.4 | 1.8 | 473604 | 3.2730774 | CS |
| 26 | -13.18 | -85.5288773524 | 15.41 | 20.63 | 1.8 | 252850 | 5.40336172 | CS |
| 52 | -6.11 | -73.2613908873 | 8.34 | 26.3789 | 1.8 | 150819 | 7.42924235 | CS |
| 156 | -11.27 | -83.4814814815 | 13.5 | 26.3789 | 1.8 | 113686 | 7.39166984 | CS |
| 260 | -11.27 | -83.4814814815 | 13.5 | 26.3789 | 1.8 | 113686 | 7.39166984 | CS |
tw0122
1 month ago
Covid19freak
2 months ago
JcOg323
2 months ago
Monksdream
5 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
